1-piperazinyl-2,7-naphthyridine | 125115-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-piperazinyl-2,7-naphthyridine
• 英文别名: 1-piperazin-1-yl-[2,7]naphthyridine；1-piperazin-1-yl-2,7-naphthyridine
• CAS: 125115-46-0
• 化学式: C₁₂H₁₄N₄
• 分子量: 214.27
• InChiKey: GFIWYMRLDKROTI-UHFFFAOYSA-N

物化性质

• 沸点：
  446.6±35.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yloxy)-butyraldehyde 、 1-piperazinyl-2,7-naphthyridine 在 三乙酰氧基硼氢化钠 、 水 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 7-[4-(4-[2,7]naphthyridin-1-yl-piperazin-1-yl)-butoxy]-1H-[1,8]naphthyridin-2-one
  参考文献：
  名称：

  WO2006/90272

  摘要：

  公开号：
• 作为产物：
  描述：

  哌嗪 、 1-氯-2,7-萘啶 以 叔丁醇 为溶剂， 以64%的产率得到1-piperazinyl-2,7-naphthyridine
  参考文献：
  名称：

  2-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxide useful as an

  摘要：

  披露了化合物2-[4-[4-(2,7-萘啶基-1-基哌嗪基)丁基]-1,2-苯并异噻唑-3(2H)-酮-1,1-二氧化物，以及制备该化合物的方法，以及其药用可接受的盐，以及将该化合物用作具有低额外锥体副作用风险的抗焦虑剂的用途。

  公开号：

  US04859671A1

文献信息

• Pyrimidine derivatives
  申请人：Sato Michitaka

  公开号：US20070197551A1

  公开（公告）日：2007-08-23

  This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.

  本发明提供了由下式表示的嘧啶衍生物，其中，环A代表碳环基团或杂环基团，X1代表氢、低碳基、氨基等，X2代表氢或低碳基，Y代表直接键或硫或氮，n代表0-4的整数，Ar代表以下式的基团，或其盐，同时表现出5-HT1A激动活性和5-HT3拮抗活性，并且对治疗诸如肠易激综合征等疾病有用。本发明进一步提供了一种IBS治疗方法，其特征在于在体内同时和协同地发挥5-HT1A激动活性和5-HT3拮抗活性，包括给予同时表现出5-HT1A激动活性和5-HT3拮抗活性的5-HT3拮抗剂，或同时给予5-HT1A激动剂和5-HT3拮抗剂，按顺序或间隔给予。
• PYRIMIDINE DERIVATIVE
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP1724267A1

  公开（公告）日：2006-11-22

  This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X1 stands for hydrogen, lower alkyl, amino, etc., X2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0 - 4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT1A agonistic activity and 5-HT3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT1A agonistic activity and 5-HT3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT3 antagonistic agent which concurrently exhibits 5-HT1A agonistic activity, or administering 5-HT1A agonistic agent and 5-HT3 antagonistic agent simultaneously, in sequence or at an interval.

  本发明提供了由式表示的嘧啶衍生物、 式中 环 A 代表碳环基团或杂环基团、 X1代表氢、低级烷基、氨基等、 X2 代表氢或低级烷基、 Y 代表直接键或硫或氮、 n 代表 0 - 4 的整数，以及 Ar 代表下式中的一个基团、 或其盐，它们同时表现出 5-HT1A 激动活性和 5-HT3 拮抗活性，可用于治疗和治疗肠易激综合征等疾病。 本发明还提供了一种肠易激综合征的治疗方法，其特征在于 5-HT1A 激动活性和 5-HT3 拮抗活性在体内同时协同发挥作用，该方法包括施用同时表现出 5-HT1A 激动活性的 5-HT3 拮抗剂，或者同时、依次或间隔施用 5-HT1A 激动剂和 5-HT3 拮抗剂。
• Synthesis and SAR of 3- and 4-substituted quinolin-2-ones: discovery of mixed 5-HT1B/5-HT2A receptor antagonists
  作者：Gary McCort、Christian Hoornaert、Michel Aletru、Colombe Denys、Olivier Duclos、Caroline Cadilhac、Eric Guilpain、Geneviève Dellac、Philip Janiak、Anne-Marie Galzin、Monique Delahaye、Frédérique Guilbert、Stephen O'Connor

  DOI：10.1016/s0968-0896(01)00118-3

  日期：2001.8

  Quinolin-2-ones bearing a heteroaryl-piperazine linked by a two carbon chain at the 3- or 4-position were synthesised and evaluated as mixed 5-HT1B/5-HT2A receptor antagonists. Potent mixed antagonists were obtained with thieno[3,2-c]pyridine derivatives. In this series, compound 2.1 (SL 65.0472) proved to be functional antagonist at both the 5-HT2A receptor (rat in vivo 5-HT-induced hypertension model) and the 5-HT1B receptor (dog in vitro saphenous vein assay). (C) 2001 Elsevier Science Ltd. All rights reserved.
• FAILLI, AMEDEO A.
  作者：FAILLI, AMEDEO A.

  DOI：——

  日期：——
• US4859671A
  申请人：——

  公开号：US4859671A

  公开（公告）日：1989-08-22